What is behind Moderna stock's recent drop in value today

Traders Union
All News
Financial News
Moderna slides 2.32% to $50.89 today

Highlights

Moderna secured multi-year strategic partnerships with the UK, Canada, and Australia, projecting $700 million in international revenue for 2025.
The company reported positive Phase 3 immune responses for its mRNA-1010 flu and RSV vaccines, with a U.S. FDA review on its mRNA flu vaccine expected by mid-2026 amid ongoing patent litigation.
Despite intraday selling pressure, technical signals indicate a high probability of price consolidation between $50.43 and $55.51 over the next week, supported by bullish weekly trend indicators.

Strategic deals and pipeline progress challenged by legal risks, weak sentiment

Moderna established multi-year strategic partnerships with the United Kingdom, Canada, and Australia, generating $700 million in projected international revenue in 2025. The company reported strong immune responses from repeat dose Phase 3 studies for its mRNA-1010 influenza and mRESVIA RSV vaccines. Moderna's U.S. FDA application for its mRNA flu vaccine has been accepted, with a review expected by mid-2026, and the company continues to address ongoing patent litigation brought by BioNTech regarding mRNA technology, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees technical signals for Moderna as mixed and short-term sentiment unresolved. He notes the price remains under the 20-day average despite holding above the 50-day and 200-day levels, leaving its recent trend fragile. Kharitonov highlights that the stock is struggling against dynamic resistance, with momentum indicators divided and intraday tone weak following a significant drop. Critical attention is drawn to ongoing legal hurdles and the persistent pressure from sellers, despite news of strategic partnerships and positive vaccine data. "Any upside here looks vulnerable — without decisive bullish momentum, setbacks toward $49.14 or lower remain a real risk."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s bullish structure remains intact as the stock sits above key medium- and long-term averages. He points out strong international partnerships and successful vaccine developments as positive catalysts, supporting the view of robust revenue streams ahead. Karapetjanc emphasizes confident buy signals from all weekly indicators and expects further growth if resistance at $53.35 is cleared. He sees the current volatility as an opportunity for active traders looking for upward momentum. "With the company’s international expansion and pipeline progress, I anticipate a test of the $55.51 upper range in the coming sessions."

Mixed momentum as bullish supports clash with intraday selling pressure

Moderna is trading just below the 20-day simple moving average at $51.69 and above both the 50-day ($49.14) and 200-day ($33.91) moving averages. This configuration suggests a positive short- and medium-term trend with long-term structural support. The nearest dynamic resistance is the Ichimoku Kijun at $53.35. Immediate dynamic support is provided by the 50-day moving average.

Momentum signals are mixed: the Moving Average Convergence Divergence (MACD) on the daily chart is neutral, while the Average Directional Index (ADX) indicates a supportive trend. The Relative Strength Index (RSI) is slightly bullish at 53.99, and the Commodity Channel Index (CCI) is neutral. Stochastic RSI fluctuates near overbought levels but is currently neutral. Bull/Bear Power (BBP) registers at 1.56, confirming buyers dominate, yet it indicates an overbought intraday state. The stock opened with a downside gap of about $0.50 and is currently trading near the session low, slipping 2.32%. Intraday volatility stands at 2.13%. The tone so far is weak after the open, with pressure from sellers despite some bullish undertones in higher timeframes. Diverging signals between oscillators and momentum indicators indicate short-term indecision.

Earlier, analysts noted that Moderna's stock was under persistent selling pressure despite technical oversold signals and the potential for a bounce. The current setup, featuring renewed international partnerships, regulatory milestones, and a high-probability bullish outlook from weekly indicators, now introduces material catalysts that traders should monitor closely for sustained upside if resistance at $53.35 is cleared.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.